Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study
Authors:
Open Access
- 2 July 2016
- journal article
- research article
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 26 (4) , 269-277
Abstract
Objective Midodrine hydrochloride is a short-acting pressor agent that raises blood pressure in the upright position in patients with orthostatic hypotension. The US Food and Drug Administration’s Subpart H approval, under which midodrine was initially approved, requires post-marketing studies to confirm midodrine’s clinical benefit in this indication. The purpose of this study was to evaluate the clinical benefit of midodrine with regard to symptom response. Methods This was a double-blind, placebo-controlled, randomized, crossover, multicenter study (NCT01518946). Following screening, patients aged ≥18 years with severe symptomatic orthostatic hypotension and on a stable dose of midodrine for at least 3 months were randomized to treatment with either their previous midodrine dose or placebo on day 1 and the respective alternate treatment on day 2. The primary endpoint measured time to syncopal symptoms or near-syncope using a 45-min tilt-table test at 1 h post-dose. Results Thirty-three patients were screened for inclusion: 19 received at least one dose of midodrine and had at least one post-dose measurement of the primary endpoint. The least-squares mean time to syncopal symptoms or near-syncope after tilt-table initiation (mean ± standard error) was 1626.6 ± 186.8 s for midodrine and 1105.6 ± 186.8 s for placebo (difference, 521.0 s; 95 % confidence interval 124.2–971.7 s; p = 0.0131). There were 15 adverse events in 10 patients; all of these were mild or moderate in severity, with none considered by the investigators to be related to midodrine. Interpretation Midodrine is a well-tolerated and clinically effective treatment for symptomatic orthostatic hypotension.Keywords
Funding Information
- Shire Development LLC
This publication has 27 references indexed in Scilit:
- Midodrine: use and current status in the treatment of hypotensionBritish Journal of Cardiology, 2012
- Hypertension, Orthostatic Hypotension, and the Risk of Falls in a Community‐Dwelling Elderly Population: The Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly of Boston StudyJournal of the American Geriatrics Society, 2011
- Relationship between orthostatic hypotension and cognitive impairment in the elderlyJournal of the Neurological Sciences, 2010
- Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project)European Heart Journal, 2009
- EFNS guidelines on the diagnosis and management of orthostatic hypotensionEuropean Journal of Neurology, 2006
- Orthostatic Hypotension Predicts Mortality in Middle-Aged AdultsCirculation, 2006
- Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrineThe American Journal of Medicine, 1993
- Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group.Hypertension, 1992
- Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha‐adrenergic agonist (midodrine)Neurology, 1988
- Corticosteroids in the Management of Orthostatic HypotensionCardiology, 1976